Insider Transactions in Q1 2024 at Kura Oncology, Inc. (KURA)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 30
2024
|
Stephen Dale Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,825
-11.06%
|
$101,325
$21.55 P/Share
|
|
Jan 29
2024
|
Stephen Dale Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,158
-7.3%
|
$121,686
$17.8 P/Share
|
|
Jan 29
2024
|
Kathleen Ford Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,496
-6.48%
|
$25,432
$17.8 P/Share
|
|
Jan 29
2024
|
Teresa Brophy Bair Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,053
-2.89%
|
$34,901
$17.8 P/Share
|
|
Jan 29
2024
|
Thomas James Doyle SVP, Finance & Accounting |
SELL
Open market or private sale
|
Direct |
2,318
-1.56%
|
$39,406
$17.8 P/Share
|
|
Jan 24
2024
|
Troy Edward Wilson President and CEO |
SELL
Open market or private sale
|
Direct |
91,052
-95.95%
|
$1,821,040
$20.23 P/Share
|
|
Jan 24
2024
|
Troy Edward Wilson President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
91,052
+48.95%
|
$455,260
$5.48 P/Share
|
|
Jan 02
2024
|
Teresa Brophy Bair Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
46,250
+39.43%
|
-
|
|
Jan 02
2024
|
Brian T. Powl Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+50.0%
|
-
|
|
Jan 02
2024
|
Thomas James Doyle SVP, Finance & Accounting |
BUY
Grant, award, or other acquisition
|
Direct |
21,250
+29.65%
|
-
|